Yau K K, Siu W T, Wong D C T, Chau C H, Li A C N, Law B K B, Li M K W
Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong, SAR, China.
Dis Esophagus. 2007;20(6):487-90. doi: 10.1111/j.1442-2050.2007.00635.x.
Primary small cell carcinoma of the esophagus (SmCC) is an uncommon aggressive tumor characterized by early systemic dissemination and poor prognosis, regardless of the methods of treatment. The optimal treatment strategy remains uncertain. A retrospective study was conducted to review the results of non-operative treatment for patients with limited and metastatic esophageal SmCC. Between 1993 and 2003, 10 patients were diagnosed to have primary esophageal SmCC in our institution. Six of them had disseminated diseases, whereas the other four had limited disease upon diagnosis. All patients were managed non-operatively by either chemotherapy and/or radiotherapy. The overall median survival was 8 months (range, 2-62 months). The survival was 4-62 months for patients with limited disease, whereas it was 2-10 months for patients with disseminated disease at initial diagnosis. In summary, the current study demonstrated satisfactory palliation could be achieved with chemo-radiation for patients with limited disease; however, the ultimate role of primary chemo-radiation for esophageal SmCC must await results from randomized trials.
原发性食管小细胞癌(SmCC)是一种罕见的侵袭性肿瘤,其特征是早期发生全身播散且预后较差,无论采用何种治疗方法。最佳治疗策略仍不明确。进行了一项回顾性研究,以评估局限性和转移性食管SmCC患者的非手术治疗结果。1993年至2003年期间,我院有10例患者被诊断为原发性食管SmCC。其中6例有播散性疾病,而另外4例诊断时疾病局限。所有患者均接受化疗和/或放疗的非手术治疗。总体中位生存期为8个月(范围2 - 62个月)。疾病局限的患者生存期为4 - 62个月,而初诊时播散性疾病患者的生存期为2 - 10个月。总之,当前研究表明,对于疾病局限的患者,放化疗可实现令人满意的姑息治疗效果;然而,原发性食管SmCC的初始放化疗的最终作用必须等待随机试验的结果。